BridgeBio Pharma (BBIO) Receivables (2021 - 2026)

BridgeBio Pharma has disclosed Receivables across 5 years of filings, most recently posting $205.2 million for Q1 2026.

• Receivables for Q1 2026 came in at $205.2 million, up 78.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $205.2 million (up 78.05% YoY), and the FY2025 annual result was $139.4 million, up 2853.07% from the prior year.
• Receivables came in at $205.2 million for Q1 2026 at BridgeBio Pharma, up from $139.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $205.2 million in Q1 2026 to a low of $2.4 million in Q4 2023.
• The 4-year median for Receivables is $115.3 million (2025), against an average of $94.3 million.
• Across the five-year window, Receivables jumped 2853.07% in 2025 and jumped 78.05% in 2026, its largest moves.
• BridgeBio Pharma's Receivables stood at $2.4 million in 2023, then soared by 100.85% to $4.7 million in 2024, then surged by 2853.07% to $139.4 million in 2025, then surged by 47.17% to $205.2 million in 2026.
• The last three Receivables figures came in at $205.2 million (Q1 2026), $139.4 million (Q4 2025), and $116.5 million (Q3 2025), per Business Quant data.